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Abstract  This  is  a  narrative  review  of  azathioprine.  This  medication  is  immunomodulatory  and
immunosuppressive,  and  it  has  been  used  widely  through  different  medical  specialties  to  mod-
ify disease.  It  has  been  proven  useful  for  several  dermatoses  and  it  has  encountered  success
when used  as  an  off-label  indication  for  other  dermatologic  diseases.  Its  mechanism  of  action
is described  thoroughly,  as  well  as  precautions  for  monitoring  adequate  levels  in  patients  using
it. Dermatologists  should  also  be  aware  of  the  possible  adverse  events  it  may  present.  In  der-
matology it  can  be  used  in  bullous  and  autoimmune  diseases,  and  in  other  conditions,  including
intractable  pruritus,  atopic  dermatitis,  photodermatoses,  psoriasis,  and  others.  Azathioprine
offers an  alternative  as  a  steroid-sparing  agent  and  this  review  helps  dermatologists  prescribe
it safely  to  all  patients  who  require  it.
© 2020  Sociedade  Brasileira  de  Dermatologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/). How to cite this article: Chavez-Alvarez S, Ocampo-Candiani J,
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zathioprine  was  first  used  to  prevent  graft-versus-host
isease.  Today  it  is  widely  used  as  an  immunomodulator,
mmunosuppressant,  and  a  steroid-sparing  agent.
It  is  a  pro-drug  that  is  rapidly  converted  to  6-
ercaptopurine  (6-MP)  by  means  of  the  purine  metabolismABD 256 1--6
athway,  and  its  therapeutic  effects  are  derived  from  its
urine  anti-metabolism.1 As  a  purine  analogue,  it  inhibits
NA  production  and  exerts  effects  on  cells  with  a  high  pro-
iferation  rate  (i.e.,  T  and  B  lymphocytes).2
lsevier Espan˜a, S.L.U. This is an open access article under the CC
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It  is  ap
roved  to  prevent  graft  vs.  host  disease  in  organ  transplant
ecipients,  severe  rheumatoid  arthritis,  systemic  lupus  ery-
hematosus,  and  atopic  dermatitis.2,3 In  dermatology,  it  is
sed  off-label  for  other  several  conditions.2,3
etabolism and pharmacodynamics
t  is  synthesized  from  6-MP  and  an  imidazolic  ring  in  the
ulfur  atom  which  stabilizes  the  molecule  and  avoids  imme-
iate  catabolism.4 This  purine  antimetabolite  inhibits  the
 phase  of  the  cell  cycle.  The  metabolism  of  endogenous
urines  produces  6-MP.5 Three  metabolic  pathways  exist
ithin  liver  and  erythrocytes:  xanthine  oxidase,  thiopurine
ethyltransferase  (TPMT),  and  hypoxanthine  phosphori-
osyltransferase.  The  latter  is  responsible  for  the  drug’s
ctivity,  while  the  first  two  are  the  main  catabolic  path-
ays  and  produce  inactive  metabolites  like  thiouric  acid
Fig.  1).5,6
For  6-MP  to  affect  the  synthesis  of  nucleic  acids,
t  needs  to  be  converted  into  thioinosinic  acid.7 This
ucleotide  inhibits  mitosis,  coenzyme  formation,  neu-
rophils,  and  monocytes,  as  well  as  suppressing  the  synthesis
f  prostaglandins  by  means  of  cyclooxygenase  (COX).7 It  has
 selective  activity  for  T  over  B  lymphocytes.8 Between  70%
nd  80%  of  the  drug  is  absorbed  within  the  gastrointesti-
al  tract  and  it  reaches  peak  serum  levels  two  hours  after
ngestion.7,9 It  does  not  cross  the  blood-brain  barrier.4
ose
dults  require  1--3  mg/kg/day  and  1--4  mg/kg/day  is  the
ediatric  dose.2,5 Therapeutic  effects  are  seen  one  to  two
onths  after  starting  the  drug.  Dose  adjustments  must  be
ade  according  to  each  patients’  response.5,8 Administra-
ion  with  meals  in  divided  doses  is  suggested.3 Maintenance
an  extend  to  93  months.1
recautions  before  treatment
t  is  advisable  to  thoroughly  explain  information  regarding
his  medication  to  the  patient.  Those  unable  to  be  closely
onitored  are  not  eligible  for  treatment.3
equest:
.  Antigens  for  hepatitis  B  and  C,  enzyme-linked
immunosorbent  assay  (ELISA)  for  HIV.
.  Human  chorionic  gonadotropin  (if  indicated).
.  Complete  blood  cell  count,  blood  chemistry,  and  liver
function  tests,  before  treatment  and  twice  a  month  for
the  first  three  months.  Finalizing  this  period,  a  bimonthly
follow-up  is  required.
.  Annual  tuberculosis  screening.2Hepatic  or  renal  malfunction  mandates  lower  doses.  If
uspension  of  the  medication  is  required,  adverse  effects
ill  gradually  diminish  because  of  persistence  of  the  active
etabolite.5
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Patients  without  a  history  of  varicella  zoster  infection
eceiving  treatment  and  recent  close  contact  with  the  virus
hould  be  promptly  treated  with  immunoglobulin.  Adminis-
ration  of  live  virus  vaccines  for  the  patient  and  relatives  is
rohibited  due  to  the  existing  risk  of  transmission.  Family
embers  should  receive  inactivated  virus  vaccines.3
Children  over  6  months  of  age  and  those  not  responding
o  safer  medications  are  eligible.  Treatment  for  short  peri-
ds  may  induce  prolonged  remissions.  Dose  tapering  must
e  done  in  six  months  up  to  one  year.4
Fertility  is  not  adversely  affected;  however,  there  is
carce  evidence.4 It  is  advisable  to  avoid  pregnancy  and  use
ontraception  during  treatment.3 Adverse  events  include  a
reterm  or  underweight  child.11 Azathioprine  passes  the  pla-
ental  barrier  and  the  fetal  liver  lacks  enzymes  required  for
ts  conversion  into  active  metabolites.9
Hematological  toxicity  and  sporadic  anomalies  are  also
escribed.  There  is  no  established  pattern  of  congenital  mal-
ormations  (which  may  include  atrial  or  ventricular  septal
efects).  The  malformation  rate  varies  from  3%  to  9%  and
ncludes  myelomeningocele,  microcephaly,  preaxial  poly-
actyly,  thymic  atrophy,  and  adrenal  hypoplasia  and/or
ypospadias.9
It  is  a  category  D  drug  in  pregnancy  (acceptable  ben-
fits  but  risks  to  fetuses).  Its  use  should  be  reserved  for
ife  threatening  diseases.13 Patients  should  receive  half  the
ose  in  the  32nd week  of  gestation  if  their  leukocyte  count
s  less  than  one  standard  deviation  below  the  mean.  This
elps  prevent  leukopenia  and/or  thrombocytopenia  in  the
aby.11 A  study  involving  pregnant  women  receiving  aza-
hioprine  for  eight  weeks  in  the  first  trimester  resulted  in
carce  evidence  linking  it  to  congenital  malformations,  low
irth  weight,  and/or  prematurity.14 In  males,  no  anomalies
n  seminal  fluid  three  months  after  initiation  of  treatment
ere  described  in  patients  with  inflammatory  bowel  disease
IBD).10
Breastfeeding  is  not  advisable  during  treatment  due
o  the  risk  of  tumorigenesis  and  increased  infections  in
nfants.15 However,  a  three-year  follow-up  study  in  chil-
ren  of  patients  with  IBD  receiving  azathioprine  found
o  significant  differences  in  the  rate  of  infections  com-
ared  with  children  of  healthy  mothers.16 Most  of  the
-MP  is  excreted  in  milk  four  hours  following  ingestion,
hough  the  quantity  ingested  by  infants  is  not  considered
ignificant.17
PMT  deficiency
PMT  is  an  inducible  enzyme  and  its  levels  vary  with
ime.2 Initial  measurement  of  this  enzyme  is  required.  Oth-
rwise,  there  is  a  risk  of  adverse  effects  or  treatment
t  subtherapeutic  doses.2 Myelosuppression  (neutropenia
nd  pancytopenia)  may  be  present  with  regular  doses.  An
nidentified  pancytopenia  may  become  lethal.5 Ten  per-
ent  of  individuals  have  low  TPMT  activity,  which  generates
hiopurine  toxicity.5 Resultant  accumulation  of  thioguanineABD 256 1--6
ucleotides  affect  bone  marrow.8 Those  with  no  TPMT  activ-
ty  should  not  be  prescribed  azathioprine.5 A  greater  activity
f  TPMT  confers  less  risk  to  induce  a myelosuppressive
esponse  (Table  1).2
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Figure  1  Azathiopr
Table  1  Thiopurine  methyltransferase  (TPMT)  levels  and
azathioprine  dosage
TPMT  levels  Dosage  of  azathioprine
<5  U Contraindicated
5--13.7  U Up  to  0.5  mg/kg/day
13.7--19  U Up  to  1.5  mg/kg/day
>19 U Up  to  2.5  mg/kg/day
Adapted from Patel et al.4
Table  2  Azathioprine  contraindications.
Relative  Absolute
Use  of  allopurinol  6  MP  hypersensitivity  or
azathioprine
Previous  treatment  with
cyclophosphamide  or
chlorambucil
Severe  active  infection
Renal failure  Altered  liver  function
Viral hepatitis,  HIV  Altered  bone  marrow  function
Previous  infection  by  VZV  Pancreatitis
Pre-malignancy Live  virus  vaccines
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Applications in dermatology
Pemphigus  vulgaris
Used  as  first-line  steroid  sparing  agent.  It  offers  better
results  as  compared  to  mycophenolate  mofetil  (MMF).5,19
Another  drug,  cyclophosphamide,  has  a  faster  onset  of
action;  however,  treatment  effectiveness  is  comparable  at
six  months.20 When  combined  with  prednisone,  final  out-
comes  are  better,  with  benefits  such  as  a  greater  number  of
patients  in  remission  and  less  adverse  effects  (Table  2).21Bullous  pemphigoid
Starting  a  steroid-sparing  agent  since  the  initiation  of
treatment  is  advisable.  Time  of  onset  of  the  therapeutic
I
a
rine  metabolism.
ffects  for  azathioprine  varies  from  one  week  to  seven
onths.  At  a  four-year  follow-up,  44%  of  patients  achieve
emission  of  the  disease.1 It  halts  disease  progression  and
romotes  re-epithelialization  as  soon  as  eight  weeks  of  start-
ng  treatment.22 MMF  is  less  hepatotoxic,  but  five  times  as
ostly.  A  faster  and  complete  cure  was  also  demonstrated
hen  compared  with  MMF  (23.8  vs.  42  days).23 However,
o  differences  in  disease  control  have  been  identified
ith  prednisolone  alone,  azathioprine  and  prednisolone,
rednisolone  with  plasmapheresis,  or  prednisolone  with  aza-
hioprine  or  MMF.24
hronic  actinic  dermatitis
t  induces  57%  to  92%  of  improvement  in  patients  when  com-
ared  with  placebo.  Dosage  varies  between  1--2.5  mg/kg.
dverse  effects  observed  in  patients  treated  with  aza-
hioprine  for  this  condition  include  three  deaths,  12--15
onths  after  stopping  treatment  (secondary  to  cerebrovas-
ular  disease,  lung  disease,  and  another  due  to  heart
isease).1 It  has  demonstrated  effectiveness  in  refractory
isease.  Drug  interactions  need  to  be  reviewed  since  these
atients  have  polypharmacy,  which  is  why  it  is  preferred
ver  cyclosporine.25
soriasis
t  may  be  indicated  for  patients  with  refractory  disease.1
t  can  be  used  in  conjunction  with  biologicals  (not  rec-
mmended  as  monotherapy).5 Combined  with  infliximab
5  mg/kg),  it  induces  improvement.27 Intermittent  pulse
onotherapy  may  be  effective  giving  500  mg  doses  admin-
stered  for  three  consecutive  days  each  month,  and  100  mg
aily  continuously  for  12  to  24  months.  Remission  may  be
chieved  for  more  than  five  years  in  some  patients.26
topic  dermatitisABD 256 1--6
nformation  is  scarce;  however,  it  has  been  shown  to  be
s  effective  as  methotrexate.1,29 It  is  recommended  for
ecalcitrant  variants  in  pediatric  patients  or  when  there  is
184
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 significant  psychosocial  impact  on  the  patient  and  their
amily.2
It  can  be  used  in  combination  and  as  a  steroid-sparing
gent.1 It  reduces  the  SAS-SAD  scale  by  26%  when  com-
ared  with  placebo  (3%)  after  three  months  of  treatment.30
hen  used  for  12  weeks,  the  activity  of  the  dermatosis
as  reduced  by  37%  vs.  20%  in  the  placebo  group.31 A  27%
mprovement  in  the  severity  scoring  of  atopic  dermatitis
SSAD)  was  also  demonstrated  after  six  months.1
utaneous  vasculitis
t  is  effective  when  combined  with  prednisolone  for  purpura,
lcers,  nail  fold  microinfarcts,  and/or  peripheral  necrosis
t  2  mg/kg.  There  is  significant  improvement  in  vasculitis
fter  18  months  of  treatment,  and  88%  of  patients  achieved
omplete  remission.  Side  effects  included  septic  arthritis,
pidural  abscess,  gastrointestinal  effects,  and  an  isolated
eath  from  renal  failure  (due  to  severe  vasculitis).1
For  leukocytoclastic  vasculitis  it  is  recommended  as  a
econd-line  therapy  in  steroid  resistant  Henoch--Schoenlein
urpura,  but  it  has  been  used  successfully  and  has  improved
he  course  of  nephritis.32
In  ANCA  vasculitis,  azathioprine  vs.  rituximab  were  com-
ared  to  maintain  remission  of  the  disease.  More  patients
emained  in  remission  at  28  months  with  rituximab  vs.
zathioprine.33
ntractable  pruritus
n  a  retrospective  study  of  patients  with  chronic  pruritus
85%  of  patients  with  symptoms  for  12  months  or  more)
ho  transiently  responded  to  a  course  of  systemic  steroids
ut  were  refractory  to  other  treatments,  azathioprine  was
nitiated,  with  a  mean  starting  dose  of  137.5  mg/day.  The
ruritus  scale  was  modified  from  a  9  to  a  1  or  2.18
onnective  tissue  diseases  (lupus)
seful  in  refractory  subacute  cutaneous  lupus  erythemato-
us,  generalized  discoid  lupus,  and  the  erosive  palmoplantar
ype,  demonstrating  a  complete  or  partial  improvement.
owell’s  syndrome  shows  good  therapeutic  response  when
ombined  with  prednisolone.8
For  systemic  lupus  erythematosus  with  cutaneous  man-
festations  and  nephritis,  1  mg/kg  daily  can  be  added  to
yclophosphamide  (0.05  to  1.00  g/m2 body  surface  per
onth  for  six  months).34
ermatomyositis
n  retrospective  case  series,  it  has  been  shown  to  be  effec-
ive.  It  is  considered  equally  effective  when  compared  to
ethotrexate.  If  patients  have  an  inadequate  response  to
hese  medications,  combined  treatment  offers  good  results
n  refractory  disease.35 It  is  also  recommended  to  prevent
elapses  for  long  periods  (one  to  three  years).36
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ther  uses  in  dermatology
n  an  open-label  pilot,  uncontrolled  study  for  moderate  and
evere  alopecia  areata  a  2  mg/kg  dose  provided  remark-
ble  improvement.37 In  a  prospective  study  with  14  patients
iagnosed  with  the  universalis  variant,  recalcitrant  to  other
ystemic  and  topical  therapies,  43%  had  a therapeutic
esponse  with  a  mean  dose  of  142  mg  daily  and  a  mean  dura-
ion  of  therapy  of  ten  months.  Total  regrowth  was  seen  in
3%  and  29%  maintained  response  at  18  months  of  follow-
p.38
One  case  with  eosinophilic  fasciitis  and  generalized  mor-
hea  was  treated  with  200  mg/day  for  two  months  with
ubsequent  tapering  to  100  mg/day.  Remission  was  main-
ained  18  months  after  treatment.39
In  sarcoidosis,  it  has  demonstrated  improvement  in  some
ases;  however,  compared  with  methotrexate,  azathioprine
xhibited  a  similar  response  but  greater  toxicity.40
Bullous  pemphigoid  and  psoriasis  can  co-exist,  and
ases  have  been  successfully  managed  with  azathioprine
50--150  mg/day).  It  prevents  reactivation  of  psoriasis  when
nterrupting  steroids.41 In  conjunction  with  acitretin  it  is
sed  for  erythrodermic  psoriasis  and  bullous  pemphigoid.42
dverse  effects/toxicity
hort  term
ausea.  This  is  the  most  frequent  dose  dependent  adverse
ffect.  It  arises  at  the  beginning  of  treatment  and  improves
ven  without  altering  the  dose.  To  avoid  it,  doses  are  started
t  their  lowest  range;  <2.5  mg/kg  reduces  abandonment  rate
y  20%.5 The  dose  can  be  split  and  taken  with  meals.3
ypersensitivity  to  azathioprine.  This  idiosyncratic  reac-
ion  is  immunologically  mediated.  It  presents  within  a  few
eeks  of  starting  the  medication.  Identification  is  essen-
ial  since  it  may  be  misinterpreted  as  a  sign  of  infection.
atients  may  have  fever,  myalgia,  arthralgia,  nausea,  hep-
titis,  interstitial  nephritis,  renal  failure,  and  pneumonitis.
utaneous  signs  include  erythema  nodosum,  Sweet’s  syn-
rome,  small  vessel  vasculitis,  acute  generalized  pustulosis,
nd  other  non-specific  dermatoses.  Hypotension  and  shock
ay  develop  in  severe  cases.44
It  is  possibly  underdiagnosed,  and  atopic  eczema  patients
re  the  most  likely  to  develop  it.  Cutaneous  signs  and  symp-
oms  resolve  five  days  after  interrupting  the  drug.5,44
edium  term
yelotoxicity.  This  is  characterized  by  leukopenia,  throm-
ocytopenia,  anemia,  and/or  pancytopenia.7 Neutropenia
s  dose  dependent.  This  serious  side  effect  may  happen
ore  often  than  presumed.  Approximately  19%  of  patients
evelop  neutropenia.5
Clinical  infection,  pharyngeal  ulceration,  ecchymosis,
nd/or  bleeding  can  lead  to  its  identification.  Monitoring
s  required  if  there  is  a  decrease  in  platelet  and  white
lood  cell  count  within  the  normal  lower  limit.  If  lym-ABD 256 1--6
hocytes  decrease  <0.50  k/uL,  it  is  advisable  to  reduce
he  dose.  If  alterations  in  platelet  count  show  <50  k/uL
nd/or  neutrophils  are  <1.0  k/uL,  a  hematology  consultation
s  recommended.3
288
289
290
291
 IN+Model
C
N
U
R
R
1
1
1
1
1
1
1
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396ARTICLE
Azathioprine:  its  uses  in  dermatology  
Infections.  There  is  increased  susceptibility  to  infections
due  to  lymphopenia  even  without  neutropenia.  Latent
tuberculosis  patients  are  at  risk  of  reactivation  when  start-
ing  treatment.5
Hepatotoxicity.  Reversible  portal  fibrosis  and/or  minimal
cholestasis  may  develop.7 Mild  changes  in  liver  function  tests
without  serious  clinical  implications  are  frequent.  There
are  two  types  of  hepatotoxicity  for  azathioprine:  idiosyn-
cratic  acute  liver  injury,  with  hepatocellular  disease  (severe
transaminase  increase)  or  cholestasis  (increase  in  alkaline
phosphatase  and  bilirubin).5 These  resolve  by  decreasing  or
withdrawing  medication.3,5 Serious  hepatotoxicity  is  rare.5
Long  term
There  is  a  risk  of  cutaneous  infections  and  hematological  or
cutaneous  neoplasms.7 However,  when  used  exclusively  for
dermatological  conditions,  this  is  unlikely  since  the  dosage
is  lower  and  time  of  use  is  shorter.1
Conclusion
Azathioprine  is  a  useful  medication  in  patients  with  complex
dermatologic  conditions  and/or  resistant  to  conventional
treatments.  It  has  been  approved  for  diseases  like  lupus,
dermatomyositis,  and  pemphigus  vulgaris.  It  is  essential  for
the  dermatologist  to  adequately  educate  the  patient  who
will  receive  the  medication  for  its  adverse  effects.  Physi-
cians  should  be  aware  that  these  undesired  effects  improve
and  resolve  when  azathioprine  is  decreased  or  interrupted.
It  is  always  recommended  to  start  at  the  lowest  possible
dose  in  order  to  improve  tolerance  and  to  avoid  permanent
discontinuation  of  a  drug  that  can  be  extremely  beneficial
for  the  patient.
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